Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLICEL LIFE SCIENCES INC.

(REPCF)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Replicel Announces Dermaprecise Trademark for Dermal Injector Product Line

10/28/2021 | 07:06am EST

RepliCel Life Sciences Inc. announced the DermaPrecise trademark for its dermal injector product portfolio. Immediate high-value medical applications being explored for the DermaPrecise Injector are for dermal and subcutaneous delivery of cell and gene therapies, antibody therapeutics, toxins, and certain medical dermatology applications. Aesthetic applications for the DermaPrecise Injector will include the injection of enzymes for fat dissolution, platelet rich plasma (PRP) for skin and hair applications, fat transfers, and certain applications of toxins and dermal fillers where there is a need to minimize injection pain and/or ensure broad, even dispersion of product as broadly as possible. The DermaPrecise injection system is supplied with single-use cartridges and multi- needle heads for use with injectables of varying viscosity including highly viscose products such as some of the newer crosslinked hyaluronic acid-based dermal fillers and antibody therapeutics. RepliCel initially developed the DermaPrecise injection system to ensure optimized, precise, and consistent delivery of its cell-based regenerative medicine products in development to reverse hair loss due to androgenetic alopecia and to regenerate the extracellular matrix under aging skin. For the rapidly growing cell and gene therapy industry, injection-related shear force can threaten to burst cells during the delivery process thus obviating the product's effectiveness. In the coming weeks, RepliCel intends publish data demonstrating the superiority of the DermaPrecise Injector, over traditional methodologies, for the delivery of cells into the skin and subcutaneous layer.


ę S&P Capital IQ 2021
All news about REPLICEL LIFE SCIENCES INC.
2021REPLICEL LIFE SCIENCES : 51-102F3 MATERIAL CHANGE REPORT - Form 6-K
PU
2021REPLICEL LIFE SCIENCES : Closed Final Tranche of Strategic Investment Commitment
PU
2021RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido
CI
2021RepliCel Life Sciences Inc. announced that it has received CAD 0.99892 million in fundi..
CI
2021RepliCel Life Sciences Inc. announced that it expects to receive CAD 0.99892 million in..
CI
2021RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021REPLICEL LIFE SCIENCES : NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS - Fo..
PU
2021REPLICEL LIFE SCIENCES : Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study ..
PU
2021RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Labora..
PU
2021RepliCel's Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to..
PU
More news
Financials
Sales 2020 0,35 M 0,28 M 0,28 M
Net income 2020 -1,58 M -1,26 M -1,26 M
Net Debt 2020 0,54 M 0,43 M 0,43 M
P/E ratio 2020 -2,90x
Yield 2020 -
Capitalization 10,9 M 8,75 M 8,73 M
EV / Sales 2019 25,8x
EV / Sales 2020 22,0x
Nbr of Employees 1
Free-Float 49,9%
Chart REPLICEL LIFE SCIENCES INC.
Duration : Period :
RepliCel Life Sciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Robert Lee Buckler President, CEO, Secretary & Director
Simon S. Ma Chief Financial Officer & Finance Director
David M. Hall Chairman
Rolf Hoffmann Chief Medical Officer
Kevin McElwee Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLICEL LIFE SCIENCES INC.13.57%9
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.73%52 665
BIONTECH SE-23.97%47 338